Early Improvement and Marriage Are Determinants of the 12-Month Treatment Outcome of Paroxetine in Outpatients with Panic Disorder.
10.9758/cpn.2017.15.4.382
- Author:
Takashi WATANABE
1
;
Mikito UEDA
;
Shin ISHIGURO
;
Yuki HAYASHI
;
Akiko AOKI
;
Masataka SHINOZAKI
;
Kazuko KATO
;
Kazufumi AKIYAMA
;
Kazutaka SHIMODA
Author Information
1. Department of Psychiatry, Dokkyo Medical University School of Medicine, Shimotsuga, Japan. takashiw@dokkyomed.ac.jp
- Publication Type:Original Article
- Keywords:
Paroxetine;
Panic disorder;
Marital status;
Treatment outcome;
Patient dropouts;
Induction of remission
- MeSH:
Drug Therapy;
Humans;
Marital Status;
Marriage*;
Outpatients*;
Panic Disorder*;
Panic*;
Paroxetine*;
Patient Dropouts;
Remission Induction;
Serotonin;
Serotonin Plasma Membrane Transport Proteins;
Single Person;
Therapeutic Uses;
Treatment Outcome*
- From:Clinical Psychopharmacology and Neuroscience
2017;15(4):382-390
- CountryRepublic of Korea
- Language:English
-
Abstract:
OBJECTIVE: In this study, we investigated the determinants of remission and discontinuation of paroxetine pharmacotherapy in outpatients with panic disorder (PD). METHODS: Subjects were 79 outpatients diagnosed with PD who took 10–40 mg/day of paroxetine for 12 months. The candidate therapeutic determinants included the serotonin transporter gene-linked polymorphic region and the −1019C/G promoter polymorphism of the serotonin receptor 1A as genetic factors, educational background and marital status as environmental factors, and early improvement (EI) at 2 weeks as a clinical factor were assessed. The Clinical Global Impression scale was used to assess the therapeutic effects of the pharmacotherapy. RESULTS: Cox proportional hazards regression was performed to investigate the significant predictive factors of remission and discontinuation. EI was only a significant predictive factor of remission. EI was a significant predictive factor of remission (hazard ratio [HR], 2.709; 95% confidence interval [CI], 1.177–6.235). Otherwise, EI and marital status were significant predictive factors of the discontinuation. EI (HR, 0.266; 95% CI, 0.115–0.617) and being married (HR, 0.437; 95% CI, 0.204–0.939) were considered to reduce the risk of treatment discontinuation. In married subjects, EI was a significant predictive factor of the discontinuation (HR, 0.160; 95% CI, 0.045–0.565). However, in unmarried subjects, EI was not a significantly predictive factor for the discontinuation. CONCLUSION: EI achievement appears to be a determinant of PD remission in paroxetine treatment. In married PD patients, EI achievement also appears to reduce a risk of discontinuation of paroxetine treatment.
